At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
ExAblate MRgFUSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
In Brief
A clinical study evaluating ExAblate MRgFUS for Bone Metastasis. Completed, enrolled 32 participants across 9 sites.
Detailed Summary
The study hypotheses is that the proportion of patients experiencing clinically significant pain relief will be at least 30% greater than the proportion experiencing worsening pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Metastasis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartSep 2013
Primary CompletionJan 2022
TodayJul 2026
First PostedApr 17, 2013
Enrollment StartSep 1, 2013
Primary CompletionJan 14, 2022
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 13.2 years ago
Interventions
ExAblate MRgFUSdevice
Focused Ultrasound Ablation